New drug ORKA-002 tested in humans for the first time
NCT ID NCT06944379
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 1 trial is the first time ORKA-002 is being tested in humans. It involves 24 healthy adults to check the drug's safety, tolerability, and how the body processes it. Participants receive a single injection of either ORKA-002 or a placebo. The study is not designed to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ORKA-002
- What could go wrong
- This is a very early Phase 1 trial with only 24 healthy people. It tests safety, not effectiveness, so it may not lead to any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oruka Therapeutics Investigative Site
Christchurch, New Zealand, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults